RCSI report: Risk of ‘conflict of interest’ on pharma payments
Royal College of Surgeons’ latest research reveals ‘substantial potential for conflicts of interest in Irish healthcare’
The lack of transparency around pharmaceutical companies paying Irish healthcare organisations and professionals has created a “substantial potential for conflicts of interest", research from the Royal College of Surgeons (RCSI) has found.
Large pharma firms including Pfizer, Roche, GlaxoSmithKline and many others paid a total of €163 million from 2015 to 2019, according to the study published in Health Policy, the academic journal.
The payments were used for a variety of activities such as consultancy work,...
Subscribe from just €1 for the first month!
With any subscription you will have access to
Unlimited multi-device access to our iPad, iPhone and Android Apps
Unlimited access to our eReader library
Exclusive daily insight and opinion seven days a week
Create alerts to never miss a subject that matters to you
Get access to exclusive offers for subscribers on gifts and experiences
Get content from Business Post, Business Post Magazines, Connected, Tatler and Food & Wine
HSE never used Citywest conference centre as isolation hub despite multimillion refurbishment
Executive leased conference centre for use as an overspill facility but never used the conference centre despite millions being spent making it habitable
Róisin Shortall: Lack of political will is derailing Sláintecare’s health reforms
It’s not good enough to blame the pandemic for the slow pace of change in Irish healthcare, and the resignation last week of two key members of the Sláintecare programme was at least partly prompted by a lack of buy-in by politicians
HSE resistance to reform led to Sláintecare resignations
HSE and the Department of Health are opposing the plan to devolve powers to six regional health hubs
Elaine Byrne: Our conservative approach to medical cannabis is prolonging people’s suffering
The licensing of cannabis medication is overly bureaucratic, the products are expensive and reimbursement limited, so some individuals are risking prosecution by growing their own